Relapsed refractory leukaemia represents a difficult to treat population of patients. The balance between perceived benefit and potential side effects along with the significant financial burden of managing multidrug resistant sepsis are factors which determine the choice of salvage regimen. Here we present our experience with the combination of Fludrabine, Cytarabine, GCSF with Bortezomib. The morphological complete response rate was 58.% with 50% of the patients achieving complete remission. With only three patients requiring ICU admission during the period of care. 66.6% of the patients went on to undergo successful hematopoietic stem cell transplantation. Thus, proving to be a possible, safer alternative to other salvage regimens